NCT01104701 - A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Type 2 Diabetes

Interventions

DRUG

exenatide once weekly

subcutaneous injection, 2 mg, once a week

DRUG

exenatide once monthly suspension

subcutaneous injection, low dose, once a month

DRUG

exenatide once monthly suspension

subcutaneous injection, medium dose, once a month

DRUG

exenatide once monthly suspension

subcutaneous injection, high dose, once a month

Trial Locations (2)

Research Site, Phoenix

Research Site, Lincoln